A lower expression level of serum miR-17-5p helps extend the survival of patients with lung cancer

our study suggests that miRNA 17 family (including miR-17, 20a, 20b) can act as TGFbetaR2 suppressor for reversing cisplatin-resistant and suppressing metastasis in non small cell lung cancer.

Our results indicated that paclitaxel resistance of lung cancer is associated with downregulation of miR-17-5p expression which might cause upregulation of BECN1 expression.

Combined overexpression of both miR-16 and miR-17 reduced the colony forming ability and paclitaxel sensitivity of paclitaxel resistant lung cancer cells.

HNF1A-AS1 promoted lung cancer cells proliferation and invasion via regulating miR-17-5p.

H19 may serve as a competing endogenous RNA (ceRNA) to modulate STAT3 by attaching miR-17 in lung cancer

Results found miR17 significantly downregulated in cisplatin (DDP)resistant nonsmall cell lung cancer (NSCLC) cells. Bioinformatics analysis identified binding sites between BLACAT1 and miR17. Therefore, lncRNA BLACAT1 may be involved in chemoresistance of NSCLC cells via miR17.

newly developed diagnostic panel consisting of exosomal miR-17-5p, CEA, CYFRA21-1 and squamous cell carcinoma antigen may have considerable clinical value in the diagnosis of non-small cell lung cancer

High miR17 expression is associated with metastasis in Non-Small-Cell lung cancer.

LncRNA MIR17HG inhibits non-small cell lung cancer by upregulating miR-142-3p to downregulate Bach-1.

lncRNA MRUL Suppressed Non-Small Cell lung cancer Cells Proliferation and Invasion by Targeting miR-17-5p/SRSF2 Axis.